On-X Heart Valve - 17mm Aortic and 23mm Mitral

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-18

Study Completion Date

2018-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines the hemodynamic and hemolytic properties of two additional smaller size valves to the On-X line of valves already approved by FDA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

NCT03022708

Heart Defect, Congenital

ACTIVE_NOT_RECRUITING NA

Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction

NCT02700100

Congenital Heart Disease

UNKNOWN NA

Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System

NCT03714412

Mitral Regurgitation

WITHDRAWN NA

Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study

NCT02428010

Mitral Valve Insufficiency

TERMINATED NA

The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study

NCT04343313

Mitral Valve Insufficiency

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to assess the safety and efficacy of the 17mm On-X Aortic Prosthetic Heart Valve and the 23mm On-X Mitral Prosthetic Heart Valve when used to replace diseased aortic or mitral valves in human subjects.

The On-X 17mm aortic valve will be implanted in approximately 20 and at least 15 patients who will be followed for at least 1 year. Patients will be any age and will require this size valve as determined in surgery but will be recruited prior to surgery based on results of preoperative screening tests.

Enrollment into the 23mm mitral arm of the study has been terminated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Valve Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Patients in one arm are recipients of the 17mm On-X Aortic Valve. Patients in the second arm are recipients of the 23mm On-X Mitral Valve. Since double valve cases are exclusionary, these two arms are mutually exclusive and non-randomized.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

17mm On-X Aortic Heart Valve

Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.

Group Type EXPERIMENTAL

17mm aortic valve (On-X )

Intervention Type DEVICE

Heart aortic valve replacement surgery: 17mm Aortic

23mm On-X Mitral Heart Valve

Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.

Enrollment into the 23mm On-X mitral arm has been terminated.

Group Type EXPERIMENTAL

23mm mitral valve (On-X)

Intervention Type DEVICE

Heart mitral valve replacement surgery: 23mm Mitral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

17mm aortic valve (On-X )

Heart aortic valve replacement surgery: 17mm Aortic

Intervention Type DEVICE

23mm mitral valve (On-X)

Heart mitral valve replacement surgery: 23mm Mitral

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

On-X prosthetic heart valve On-X prosthetic heart valve

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients of any age; unless waived by local IRB assent of the patient and in all cases consent of parent or legally authorized representative is required if a patient is under the age of majority and not legally emancipated.
2. Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups.
3. Patients who are in sufficient satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk, (i.e., likely to survive one year postoperatively).
4. Patients who require an isolated aortic valve replacement size 17 mm or isolated mitral valve replacement size 23mm.
5. Patients who are geographically stable and willing to return to the implanting center for follow-up visits.
6. Patients or legally authorized representatives who are adequately informed of their participation in the clinical study and what will be required of them in order to comply with the protocol.
7. Patients requiring concomitant cardiovascular surgery, such as coronary bypass may be included in the study.

Exclusion Criteria

1\. Patients who are pregnant, planning to become pregnant or are lactating. 2 Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient.

3 Patients who have a documented history of substance (drug or alcohol) abuse or are prison inmates.

4\. Patients with a previous prosthetic valve, where it is not being replaced by a study valve, or patients requiring multiple valve replacement.

5\. Patients with active endocarditis or active myocarditis. 6 Patients who require tricuspid or pulmonic valve replacement. 7. Patients who have not agreed to return for the required number of follow-up visits or who are geographically unavailable for follow-up.

8\. Patients who cannot be maintained on long-term anticoagulant therapy. 9. Patients with non-cardiac illness resulting in a life expectancy of less than 1-year.

10\. Patients previously enrolled and implanted in this trial may not re-enter after withdrawal.

11\. Patients already enrolled in another investigational device or drug study (nor can enrolled patients be enrolled in other studies).

12\. Patients with acute preoperative neurological deficit, myocardial infarction, or cardiac event who have not returned to baseline for at least 30-days prior to enrollment.

13\. Patients with aortic aneurysm or other medical condition that creates a higher than usual risk of surgical complication.

14\. Patients who are prisoners or mentally ill, and pediatric patients who are incapable of understanding their assent as judged by the principal investigator.

Eligible Sex

ALL

Accepts Healthy Volunteers

No